ଏମ୍ପାଗ୍ଲିଫ୍ଲୋଜିନ

ଏମ୍ପାଗ୍ଲିଫ୍ଲୋଜିନ
Clinical data
Trade names	Jardiance, others
Synonyms	BI-10773
AHFS/Drugs.com	monograph
MedlinePlus	a614043
data	EU EMA: yes; US DailyMed: Jardiance;
Pregnancy; category	AU: D ; US: N (Not classified yet) ; ;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Identifiers
	IUPAC name (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol;
ECHA InfoCard	100.122.058
Chemical and physical data
Formula	C23H27ClO7
Molar mass	୪୫୦.୯୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl;
	InChI InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1; Key:OBWASQILIWPZMG-QZMOQZSNSA-N;

ଏମ୍ପାଗ୍ଲିଫ୍ଲୋଜିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବ୍ୟବସାୟୀକ ନାମ ଜାର୍ଡିଆନ୍ସ, ଏକ ଔଷଧ ଯାହା ଟାଇପ୍-୨ ମଧୁମେହ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ଉପ‌ଯୁକ୍ତ ଖାଦ୍ୟ ଏବଂ ବ୍ୟାୟାମ ସହିତ ବ୍ୟବହୃତ ହୁଏ | ^[୪] ^[୫] ମେଟଫର୍ମିନ ଏବଂ ସଲଫୋନିଲୁରିଆ ଅପେକ୍ଷା ଏହା କମ୍ ପସନ୍ଦ କରାଯାଏ | ^[୬] ଏହା ମେଟଫର୍ମିନ୍ କିମ୍ବା ଇନସୁଲିନ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୋଇପାରେ | ^[୭] ^[୮] ଟାଇପ୍ 1 ଡାଇବେଟିସ୍ ପାଇଁ ଏହା ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୭] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୭]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୂତ୍ରାଶୟ ସଂକ୍ରମଣ, କବକ ସଂକ୍ରମଣ ଏବଂ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା ଅନ୍ତର୍ଭୁକ୍ତ | ^[୪] କ୍ୱଚିତ୍ କିନ୍ତୁ ଅଧିକ ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଫୋର୍ନିଅରସ ଗାଙ୍ଗ୍ରିନ ନାମକ ଏକ ଚର୍ମ ସଂକ୍ରମଣ ଏବଂ ସାଧାରଣ ରକ୍ତରେ ଶର୍କରା ସ୍ତର ସହିତ ମଧୁମେହିକ କିଟୋଏସିଡୋସିସ ହୋଇପାରେ| ^[୭] ^[୯] ଗର୍ଭାବସ୍ଥାରେ ଏବଂ ସ୍ତନ୍ୟପାନରେ ବ୍ୟବହାର କରିବା ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୬] ଉଲ୍ଲେଖନୀୟ ବୃକ୍‌କ ରୋଗୀ ବ୍ୟକ୍ତିଙ୍କଠାରେ ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ, ଯଦିଓ ଏହା ସାମାନ୍ୟ ବୃକ୍‌କ ସମସ୍ୟାର ପ୍ରଗତିକୁ ମନ୍ଥର କରିବାରେ ସାହାଯ୍ୟ କରିଥାଏ | ^[୭] ^[୫] ସୋଡ଼ିଅମ ଗ୍ଲୁକୋଜ କୋ-ଟ୍ରାନ୍ସପୋର୍ଟର-୨ର ଏମ୍ପାଗ୍ଲିଫ୍ଲୋଜିନ ଏକ ଇନହିବିଟର ବା ପ୍ରତିବନ୍ଧକ ଅଟେ ଏବଂ ମୂତ୍ରରେ ଚିନି ନିଷ୍କାଶନ ବୃଦ୍ଧି କରି କାର୍ଯ୍ୟକ୍ଷମ ହୋଇଥାଏ | ^[୭]

୨୦୧୪ରେ ଆମେରିକାରେ ଏବଂ ୟୁରୋପୀୟ ୟୁନିଅନରେ ଏମ୍ପାଗ୍ଲିଫ୍ଲୋଜିନ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୧୦] ^[୧୧] ^[୧୨] ^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୧୯ମସିହାରେ ଏହାର ମୂଲ୍ୟ ୩୬.୫୯ ପାଉଣ୍ଡ ଥିଲା । ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୪୨୨ ଡଲାର ଅଟେ । ^[୧୩] ୨୦୧୭ ମସିହାରେ ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୨୮ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଦୁଇ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା | ^[୧୪] ^[୧୫]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Empagliflozin (Jardiance) Use During Pregnancy". Drugs.com. 30 August 2018. Retrieved 10 February 2020.
↑ "Jardiance 10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 10 February 2020.
↑ "Jardiance 25 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 23 October 2019. Retrieved 10 February 2020.
↑ ^୪.୦ ^୪.୧ ^୪.୨ "Empagliflozin Monograph for Professionals". Drugs.com. AHFS. Retrieved 21 December 2018.
↑ ^୫.୦ ^୫.୧ Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 61 (12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.
↑ ^୬.୦ ^୬.୧ ^୬.୨ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 691. ISBN 9780857113382.
↑ ^୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ ^୭.୪ ^୭.୫ "Empagliflozin Monograph for Professionals". Drugs.com. AHFS. Retrieved 21 December 2018.
↑ Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 61 (12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.
↑ "FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 2019-02-09. Retrieved 2019-03-18.
↑ "Drug Approval Package: Jardiance (empagliflozin) Tablets NDA #204629". U.S. Food and Drug Administration (FDA). 8 September 2014. Retrieved 10 February 2020.
↑ "Jardiance EPAR". European Medicines Agency (EMA). Retrieved 10 February 2020.
↑ "Jardiance: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.
↑ "NADAC". Centers for Medicare and Medicaid Services. 2019-02-27. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
↑ "Empagliflozin - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[Drugs.com_pregnancy-1] ୧.୦ ^୧.୧ "Empagliflozin (Jardiance) Use During Pregnancy". Drugs.com. 30 August 2018. Retrieved 10 February 2020.

[2] "Jardiance 10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 10 February 2020.

[3] "Jardiance 25 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 23 October 2019. Retrieved 10 February 2020.

[AHFS2018-4] ୪.୦ ^୪.୧ ^୪.୨ "Empagliflozin Monograph for Professionals". Drugs.com. AHFS. Retrieved 21 December 2018.

[EU2018-5] ୫.୦ ^୫.୧ Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 61 (12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.

[BNF76-6] ୬.୦ ^୬.୧ ^୬.୨ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 691. ISBN 9780857113382.

[autogen4-7] ୭.୦ ^୭.୧ ^୭.୨ ^୭.୩ ^୭.୪ ^୭.୫ "Empagliflozin Monograph for Professionals". Drugs.com. AHFS. Retrieved 21 December 2018.

[autogen3-8] Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB (December 2018). "Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 61 (12): 2461–2498. doi:10.1007/s00125-018-4729-5. PMID 30288571.

[FDA2019SE-9] "FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration (FDA). 2019-02-09. Retrieved 2019-03-18.

[FDA_Approval-10] "Drug Approval Package: Jardiance (empagliflozin) Tablets NDA #204629". U.S. Food and Drug Administration (FDA). 8 September 2014. Retrieved 10 February 2020.

[Jardiance_EPAR-11] "Jardiance EPAR". European Medicines Agency (EMA). Retrieved 10 February 2020.

[12] "Jardiance: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.

[NADAC2019-13] "NADAC". Centers for Medicare and Medicaid Services. 2019-02-27. Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-14] "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.

[ref1-15] "Empagliflozin - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

[୪]

[୫]

[୬]

[୭]

[୮]

[୧]

[୨]

[୩]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]

[୧୪]

[୧୫]